Ftse Mib
35.398,82
-0,03%
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
NASDAQ
16.685,97
-0,07%
Bitcoin
66.801,59
-0,42%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Freeline Therapeutics Holdings PLC (FRLN) Freeline Therapeutics Holdings PLC (FRLN) Notizie

Freeline Therapeutics Holdings PLC

FRLN
6,48
0,00 (0,00%)
17 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Ricevuta di Deposito
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
24/4/202422:00GLOBEFreeline to Present New Data on its Gaucher and Parkinson’s..
26/2/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
22/2/202422:38EDGAR2Form S-8 POS - Securities to be offered to employees in..
22/2/202422:28EDGAR2Form POS AM - Post-Effective amendments for registration..
20/2/202421:22EDGAR2Form SC 13E3/A - Going private transaction by certain..
20/2/202413:13EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/2/202413:00GLOBEAcquisition of Freeline by Syncona Becomes Effective
12/2/202422:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/2/202418:00GLOBEFreeline Shareholders Approve Acquisition by Syncona
18/1/202422:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
17/1/202422:17EDGAR2Form SC 13E3/A - Going private transaction by certain..
08/12/202323:21EDGAR2Form SC 13E3 - Going private transaction by certain issuers
01/12/202314:56EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
22/11/202315:20EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
22/11/202313:30GLOBESyncona to Acquire Freeline Therapeutics
25/10/202312:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
25/10/202308:01GLOBEFreeline Presents Positive New Data from Phase 1/2 GALILEO-1..
18/10/202313:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
16/10/202313:00GLOBEFreeline to Present New Clinical Data for FLT201 in Gaucher..
06/10/202322:52EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/10/202313:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/10/202313:00GLOBEFreeline Reports Positive Initial Clinical Data from First..
15/8/202313:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
15/8/202313:00GLOBEFreeline Reports Second Quarter 2023 Financial Results and..
08/8/202313:30GLOBEFreeline Therapeutics to Host Second Quarter 2023 Financial..
31/7/202313:30GLOBEFreeline to Participate in Upcoming Investor Conferences
25/7/202313:30GLOBEFreeline to Host Virtual KOL Event on its Gene Therapy..
26/6/202313:30GLOBEFreeline Announces First Patient Dosed with Its Novel Gene..
02/6/202314:00GLOBEFreeline to Present at 2023 Jefferies Healthcare Conference
30/5/202313:30GLOBEFreeline Reports First Quarter 2023 Financial Results and..
22/5/202314:00GLOBEFreeline Granted ILAP Designation in United Kingdom by MHRA..
Apertura: Min: Max:
Chiusura: 6,48

La tua Cronologia

NASDAQ
FRLN
Freeline Therapeutics
NYSE
CUDA
BARRACUDA NETWORKS INC
BIT
P14WB6
BNP Paribas Issuance
ASX
RIOIWK
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network